Correction to: Synergism between the phosphatidylinositol 3-kinase p110β isoform inhibitor AZD6482 and the mixed lineage kinase 3 inhibitor URMC-099 on the blockade of glioblastoma cell motility and focal adhesion formation
Cancer Cell Int. 2021 Jul 28;21(1):403.
doi: 10.1186/s12935-021-02028-1.
1 Department of Neurosurgery, Shenzhen Second People's Hospital/The First Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen, 518035, China.
2 Department of Neurosurgery, People's Hospital of Longhua District, Shenzhen, 518109, China.
3 Epilepsy Center, Guangdong 999 Brain Hospital, Guangzhou, 510510, China.
4 Department of Neurosurgery/Neuro‑Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, China.
5 Department of Neurosurgery, Shenzhen Second People's Hospital/The First Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen, 518035, China. wpli@szu.edu.cn.